Andrea Porpiglia
Surgical Oncology · Philadelphia, PANPI 1306010608
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Elucent Medical accounts for 63.8% of it on its own, with 31 other manufacturers making up the rest. Among surgical oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $117.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elucent Medical$7K
- Axogen$1K
- Intuitive Surgical$1K
- Amgen$255
- Johnson & Johnson$166
- Bristol Myers Squibb$157
- plus $895 from 26 others
What the payments were for
- Consulting fees$2,40021%
- Speaking & faculty fees$4,15037%
- Travel & lodging$2,76625%
- Food & beverage$1,93117%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elucent Medical | 5 | $7,192 |
| Axogen | 5 | $1,468 |
| Intuitive Surgical | 6 | $1,144 |
| Amgen | 15 | $255 |
| Johnson & Johnson(2 entities) | 6 | $166 |
| Bristol Myers Squibb | 10 | $157 |
| AstraZeneca(2 entities) | 7 | $121 |
| Novartis | 3 | $64 |
| Astellas Pharma US Inc | 2 | $56 |
| Stemline Therapeutics Inc. | 3 | $56 |
| Eisai Inc. | 3 | $55 |
| Ipsen Biopharmaceuticals, Inc | 2 | $46 |
| Puma Biotechnology, Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Merck | 1 | $33 |
| Incyte Corporation | 2 | $32 |
| AMAG Pharmaceuticals, Inc. | 2 | $30 |
| AbbVie | 2 | $28 |
| Boehringer Ingelheim | 1 | $28 |
| Sobi, Inc | 1 | $27 |
| Tesaro, Inc. | 2 | $27 |
| Bayer | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 2 | $25 |
| Lilly USA, LLC | 1 | $23 |
| Accuray Incorporated | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Covidien LP | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Fortovia Therapeutics, Inc. | 1 | $15 |
| TELA Bio, Inc. | 1 | $14 |
| Spectrum Pharmaceuticals Inc. | 1 | $12 |
| Aurobindo Pharma USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AXOGUARD$2,751
- AXOGUARD HA+ NERVE PROTECTOR$1,375
- AxoGuard Nerve Cap$1,375
- Da Vinci Surgical System$1,101
How this compares
$11,277 in reported general payments places this provider in the 95th percentile of 78 surgical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ibuprofen | 17 | $37 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Philadelphia
- Richard BleicherPhiladelphia$53K
- Nestor EsnaolaPhiladelphia$17K
- Mark EtheringtonPhiladelphia$6K
- Anthony VillanoPhiladelphia$4K
- Stephanie GrecoPhiladelphia$3K
- James SunPhiladelphia$3K
- John RidgePhiladelphia$3K
- Steven StandifordPhiladelphia$487
- Alliric WillisPhiladelphia$254
- Jennifer ZhangPhiladelphia$200
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.